<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02802267</url>
  </required_header>
  <id_info>
    <org_study_id>ICT8</org_study_id>
    <nct_id>NCT02802267</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Inecalcitol With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy</brief_title>
  <official_title>Efficacy Study of Inecalcitol in Combination With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hybrigenics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hybrigenics Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effect of the addition of inecalcitol to decitabine treatment on overall&#xD;
      survival in previously untreated AML patients aged 65 years or more who are randomly assigned&#xD;
      to receive decitabine with or without inecalcitol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>inecalcitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two tablets of Inecalcitol 2mg each (total 4mg) taken orally every other day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two tablets of placebo 2mg each (total 4mg) taken orally every other day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inecalcitol</intervention_name>
    <description>vitamin D receptor agonist</description>
    <arm_group_label>inecalcitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • Patients aged 65 to &lt; 75 years with at least one non severe comorbidity ie disease or&#xD;
        syndrome with mild to moderate clinical or diagnostic observations or lab abnormalities&#xD;
        which could increase the risk of toxicity and/or early death of intensive chemotherapy in&#xD;
        the opinion of the investigator and are not contra-indicated for non-intensive&#xD;
        chemotherapy.&#xD;
&#xD;
        or ≥ 75 years with or without any comorbidity at the time of the informed consent&#xD;
        signature;&#xD;
&#xD;
        • Newly diagnosed, untreated de novo or secondary AML according to WHO classification;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior or current treatment with chemotherapy for any myeloid disorder (excluding&#xD;
             hydroxyurea) or radiotherapy for extramedullary involvement within 2 weeks of&#xD;
             randomization;&#xD;
&#xD;
          -  Prior treatment with decitabine, azacitidine, or cytarabine;&#xD;
&#xD;
          -  Prior malignancies for 5 years with exception of basal cell, squamous cell carcinoma&#xD;
             of the skin, or carcinoma &quot; in situ &quot; of the cervix or breast;&#xD;
&#xD;
          -  Chronic myelogenous or acute promyelocytic leukaemia;&#xD;
&#xD;
          -  Known CNS involvement;&#xD;
&#xD;
          -  Patient eligible to bone marrow or stem cell transplant;&#xD;
&#xD;
          -  WBC ≥ 30.000/mm3;&#xD;
&#xD;
          -  Impaired renal function with Creatinine clearance &lt; 30 mL/min/1.73m² according to the&#xD;
             MDRD formula;&#xD;
&#xD;
          -  Serum bilirubin ≥ 2.5 x ULN and/or AST and/or ALT ≥ 2.5 x ULN (upper limit of normal&#xD;
             value);&#xD;
&#xD;
          -  Calcemia ≥ 2.65 mmol/L (106 mg/L) at screening assessment (corrected with&#xD;
             albuminemia);&#xD;
&#xD;
          -  History of diseases known to be associated with calcium disorders: ongoing&#xD;
             hyperparathyroidism, sarcoidosis….;&#xD;
&#xD;
          -  Presence or history of symptomatic kidney stones in the last 5 years;&#xD;
&#xD;
          -  Hypersensitivity to any of the excipients of decitabine (Potassium dihydrogen&#xD;
             phosphate (E340) ; Sodium hydroxide (E524) ; Hydrochloric acid (for pH adjustment) or&#xD;
             to the excipient of inecalcitol tablets (lactose);&#xD;
&#xD;
          -  Current use of drugs known to influence serum calcium (such as thiazide diuretics,&#xD;
             teriparatide, calcitonin and multivitamin supplements containing &gt; 400 IU of vitamin D&#xD;
             or calcium);&#xD;
&#xD;
          -  Current use of digitalis;&#xD;
&#xD;
          -  Current use of drugs which could influence bioavailability of inecalcitol (such as&#xD;
             magnesium-containing antacids, bile-resin binders);&#xD;
&#xD;
          -  Use of any other experimental drug or therapy or vitamin D supplementation within 4&#xD;
             weeks of randomization;&#xD;
&#xD;
          -  Known HIV;&#xD;
&#xD;
          -  Patients who are eligible for intensive induction therapy with curative intent;&#xD;
&#xD;
          -  Refractory congestive heart failure;&#xD;
&#xD;
          -  Active infection resistant to anti-infective therapy;&#xD;
&#xD;
          -  Documented pulmonary disease with DLCO ≤ 65% or FEV1≤ 65%, or dyspnea at rest or&#xD;
             requiring oxygen, or any pleural neoplasm or uncontrolled lung neoplasm;&#xD;
&#xD;
          -  Liver cirrhosis Child B or C or acute viral hepatitis;&#xD;
&#xD;
          -  Current mental illness requiring psychiatric hospitalization, institutionalization or&#xD;
             intensive outpatient management, or current cognitive status that produces dependence&#xD;
             (as confirmed by the specialist) not controlled by the caregiver;&#xD;
&#xD;
          -  Uncontrolled neoplasia;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois Dufour-Lamartinie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hybrigenics Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shankar Srinivasan, PhD</last_name>
    <phone>+1-2246221775</phone>
    <email>ssrinivasan@hybrigenics.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Francois Dufour-Lamartinie, MD</last_name>
    <phone>+33-158103805</phone>
    <email>jfdufour@hybrigenics.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Scripps Health</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marin Xavier, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Boyka S Petrov</last_name>
      <email>Petrov.Boyka@scrippshealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Center-Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy M Pantin, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Christine Sanchez</last_name>
      <email>csanchez@augusta.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khin Win, MBBS, CCRC</last_name>
      <email>khin.win@usoncology.com</email>
    </contact>
    <contact_backup>
      <last_name>Tiffany Gordon</last_name>
      <email>tiffany.gordon@usoncology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Edwin Kingsley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Cancer Care Alliance</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaylee Deutsch, MHA, CCRP</last_name>
      <email>kdeutsch@nmcca.org</email>
    </contact>
    <contact_backup>
      <last_name>April Encee, RN, OCN</last_name>
      <email>aencee@salud.unm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cecilia Arana-Yi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke Cancer Institute, Duke Univ Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Rizzieri, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Rachel Stowe</last_name>
      <email>rachel.stowe@duke.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Texas; M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Cortes, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Jane A Autry</last_name>
      <email>JAAutry@mdanderson.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>ProHealth Care Inc</name>
      <address>
        <city>Waukesha</city>
        <state>Wisconsin</state>
        <zip>53188</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dawn Minikel</last_name>
      <email>dawn.minikel@phci.org</email>
    </contact>
    <contact_backup>
      <last_name>Amelia Crouse</last_name>
      <email>amelia.crouse@phci.org</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy Wassenaar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Necker Hospital- APHP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Hermine, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>June 13, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

